Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
10.03. | Galderma @ AAD 2024: New Data Demonstrate the Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in Atopic Dermatitis | 364 | Business Wire | Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term... ► Artikel lesen | |
10.03. | Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis | 498 | Business Wire | Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib's potential role in treating prurigo nodularis... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
EVOTEC | 3.973 |
TESLA | 3.336 |
DEUTSCHE BANK | 2.494 |
NEL | 1.857 |
BYD | 1.724 |
NVIDIA | 1.405 |
BAYER | 1.265 |
TUI | 1.253 |
SUPER MICRO COMPUTER | 1.055 |
RHEINMETALL | 977 |
AIXTRON SE | 893 |
COMMERZBANK | 804 |
PHILIPS | 777 |
BASF | 752 |
RWE | 729 |
MERCEDES-BENZ | 697 |
JINKOSOLAR | 693 |
AMAZON | 651 |
META PLATFORMS | 650 |
PLUG POWER | 644 |
THYSSENKRUPP | 624 |
DELIVERY HERO | 618 |
HEIDELBERGER DRUCK | 604 |
SIEMENS ENERGY | 580 |
PAYPAL | 541 |